Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution.
作者： Signe Regner Michaelsen , Ib Jarle Christensen , Kirsten Grunnet , Marie-Thérése Stockhausen , Helle Broholm
关键词: Temozolomide 、 Combined Modality Therapy 、 Young adult 、 Internal medicine 、 Dacarbazine 、 Oncology 、 Bevacizumab 、 Observational study 、 Cohort 、 Disease 、 Medicine
摘要: Background Although implementation of temozolomide (TMZ) as a part primary therapy for glioblastoma multiforme (GBM) has resulted in improved patient survival, the disease is still incurable. Previous studies have correlated various parameters to although no single parameter yet been identified. More and new approaches identify best worst performing patients are therefore great demand.
biomedcentral.com
springer.com
core.ac.uk
paperity.org参考文章(55)
A. D. Colevas, A. Setser, The NCI Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 is the new standard for oncology clinical trials Journal of Clinical Oncology. ,vol. 22, pp. 6098- 6098 ,(2004) , 10.1200/JCO.2004.22.90140.6098
Bahman Emami, Tolerance of Normal Tissue to Therapeutic Radiation Reports of Radiotherapy and Oncology. ,vol. 1, ,(2013)
David A. Reardon, Scott Turner, Katherine B. Peters, Annick Desjardins, Sridharan Gururangan, John H. Sampson, Roger E. McLendon, James E. Herndon, Lee W. Jones, John P. Kirkpatrick, Allan H. Friedman, James J. Vredenburgh, Darell D. Bigner, Henry S. Friedman, A Review of VEGF/VEGFR-Targeted Therapeutics for Recurrent Glioblastoma Journal of The National Comprehensive Cancer Network. ,vol. 9, pp. 414- 427 ,(2011) , 10.6004/JNCCN.2011.0038
Nader Sanai, Mitchel S. Berger, Recent surgical management of gliomas. Advances in Experimental Medicine and Biology. ,vol. 746, pp. 12- 25 ,(2012) , 10.1007/978-1-4614-3146-6_2
Tumor Angiogenesis: A Quantitative Method for Histologic Grading Journal of the National Cancer Institute. ,vol. 48, pp. 347- 356 ,(1972) , 10.1093/JNCI/48.2.347
D R Macdonald, T L Cascino, S C Schold, J G Cairncross, Response criteria for phase II studies of supratentorial malignant glioma. Journal of Clinical Oncology. ,vol. 8, pp. 1277- 1280 ,(1990) , 10.1200/JCO.1990.8.7.1277
Hans Skovgaard Poulsen, Kirsten Grunnet, Morten Sorensen, Preben Olsen, Benedikte Hasselbalch, Knud Nelausen, Michael Kosteljanetz, Ulrik Lassen, Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours Acta Oncologica. ,vol. 48, pp. 52- 58 ,(2009) , 10.1080/02841860802537924
W K A Yung, R E Albright, J Olson, R Fredericks, K Fink, M D Prados, M Brada, A Spence, R J Hohl, W Shapiro, M Glantz, H Greenberg, R G Selker, N A Vick, R Rampling, H Friedman, P Phillips, J Bruner, N Yue, D Osoba, S Zaknoen, V A Levin, A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse British Journal of Cancer. ,vol. 83, pp. 588- 593 ,(2000) , 10.1054/BJOC.2000.1316
Motoo Nagane, Yoshitaka Narita, Kazuhiko Mishima, Alexander Levitzki, Antony W. Burgess, Webster K. Cavenee, H. J. Su Huang, Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor Journal of Neurosurgery. ,vol. 95, pp. 472- 479 ,(2001) , 10.3171/JNS.2001.95.3.0472
Allison Quick, Disha Patel, Mersiha Hadziahmetovic, Arnab Chakravarti, Minesh Mehta, Current therapeutic paradigms in glioblastoma. Reviews on Recent Clinical Trials. ,vol. 5, pp. 14- 27 ,(2010) , 10.2174/157488710790820544